Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.46 |
| ▸ | FDPS | P14324 | 2/20 | 0.42 |
| ▸ | BLM | P54132 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | TYMS | P04818 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PGK1 | P00558 | 1/20 | 0.31 |
| ▸ | PGK2 | P07205 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL4877969 | 1.00 | CA2 (0.50) | CA2SLC34A1FDPSBLMTDP1 | |
| Phosphoric Acid SCHEMBL8535676 | 1.00 | CA2 (0.50) | CA2SLC34A1FDPSBLMTDP1 | |
| Phosphoric Acid SCHEMBL9402752 | 1.00 | CA2 (0.50) | CA2SLC34A1FDPSBLMTDP1 | |
| Phosphoric Acid SCHEMBL244903 | 1.00 | — | — | |
| Phosphoric Acid SCHEMBL11149488 | 1.00 | CA2 (0.50) | CA2SLC34A1FDPSBLMTDP1 | |
| Phosphoric Acid SCHEMBL11424284 | 1.00 | CA2 (0.50) | CA2SLC34A1FDPSBLMTDP1 | |
| Phosphoric Acid SCHEMBL7781604 | 1.00 | CA2 (0.50) | CA2SLC34A1FDPSBLMTDP1 | |
| Phosphoric Acid SCHEMBL5141451 | 1.00 | CA2 (0.50) | CA2SLC34A1FDPSBLMTDP1 | |
| Phosphoric Acid SCHEMBL22117079 | 1.00 | CA2 (0.50) | CA2SLC34A1FDPSBLMTDP1 | |
| Phosphoric Acid SCHEMBL9450632 | 1.00 | CA2 (0.50) | CA2SLC34A1FDPSBLMTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 498 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230138662-A1 | COMPOSITION AND METHOD FOR STIMULATING PLANT GROWTH AND PRODUCTIVITY | BUTLER ANDREW (CA) | 2023-05-04 | — | — | US | claimed |
| EP-3718533-A1 | STABLE FIXED DOSE PHARMACEUTICAL COMPOSITION COMPRISING MOMETASONE AND OLOPATADINE | Glenmark Specialty S.A. (CH) | 2020-10-07 | — | — | EP | claimed |
| CN-111434773-A | Recombinant yeast for high-yield sandalwood oil and construction method and application thereof | 天津大学 | 2020-07-21 | — | — | CN | claimed |
| US-8309605-B2 | Enhanced bimatoprost ophthalmic solution | ALLERGAN, INC. (US) | 2012-11-13 | — | — | US | claimed |
| WO-2026090034-A1 | AGENTS FOR TREATMENT OF OPTIC CONDITIONS | Vision Pharma Pty Ltd (AU) | 2026-04-30 | — | — | WO | disclosed |
| US-20260108624-A1 | METHODS AND COMPOSITIONS FOR TRANSPORT, STORAGE, AND DELIVERY OF NUCLEIC ACIDS AND OTHER MOLECULES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260083729-A1 | METHODS FOR TREATMENT OF BONE MARROW FAILURE AND RELATED CONDITIONS | IMAGO BIOSCIENCES, INC. (US) | 2026-03-26 | — | — | US | disclosed |
| US-20260049123-A1 | BISPECIFIC ANTIBODIES PROMOTE NATURAL KILLER CELL-MEDIATED ELIMINATION OF HIV-1 RESERVOIR CELLS | UNIV JOHNS HOPKINS (US) | 2026-02-19 | — | — | US | disclosed |
| EP-3837286-B1 | ANTIBODIES TO HUMAN ZNT8 | UNIV JOHNS HOPKINS (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4673584-A1 | SOLID MOLDED SULFITE-BASED OXYGEN SCAVENGER COMPOSITION AND METHOD OF MANUFACTURE | NCH Corporation (US) | 2026-01-07 | — | — | EP | disclosed |
| US-20250339549-A1 | METHODS FOR THE DETECTION AND TREATMENT OF NON-SMALL-CELL LUNG CANCER | UNIV TEXAS (US) | 2025-11-06 | — | — | US | disclosed |
| EP-4637853-A1 | METHOD OF MANUFACTURING A HYDROGEL USEFUL FOR PREVENTING POST-SURGICAL ADHESIONS | Covestro Deutschland AG (DE) | 2025-10-29 | — | — | EP | disclosed |
| US-5147409-A | Shrinkage and pulling resistance; improved bleaching, dyeing | NIPPON CHEMICAL INDUSTRIAL CO., LTD. (JP) | 1992-09-15 | — | — | US | disclosed |
| EP-0478637-A4 | CALCIUM CHLORIDE HEXAHYDRATE FORMULATIONS FOR LOW TEMPERATURE HEAT STORAGE APPLICATIONS | — | 1992-08-12 | — | — | EP | disclosed |
| EP-0472620-A4 | BROMO-CONTAINING PERFLUOROPOLYMERS HAVING IODINE CURESITES | — | 1992-05-06 | — | — | EP | disclosed |
| EP-0478637-A1 | CALCIUM CHLORIDE HEXAHYDRATE FORMULATIONS FOR LOW TEMPERATURE HEAT STORAGE APPLICATIONS | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 1992-04-08 | — | — | EP | disclosed |
| EP-0472620-A1 | BROMO-CONTAINING PERFLUOROPOLYMERS HAVING IODINE CURESITES. | DU PONT (US) | 1992-03-04 | — | — | EP | disclosed |
| WO-1991000324-A1 | CALCIUM CHLORIDE HEXAHYDRATE FORMULATIONS FOR LOW TEMPERATURE HEAT STORAGE APPLICATIONS | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 1991-01-10 | — | — | WO | disclosed |
| WO-1990014370-A1 | BROMO-CONTAINING PERFLUOROPOLYMERS HAVING IODINE CURESITES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-11-29 | — | — | WO | disclosed |
| US-4196202-A | Carcinostatic composition containing 3-N-o-toluyl-5-fluorouracil producing the same | OKADA TAIJI | 1980-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260083729-A1 | METHODS FOR TREATMENT OF BONE MARROW FAILURE AND RELATED CONDITIONS | KDM1A, KDM1B, KDM3A | CA2 3354/4885SLC34A1 4439/4885FDPS 4433/4885 |
| US-20260108624-A1 | METHODS AND COMPOSITIONS FOR TRANSPORT, STORAGE, AND DELIVERY OF NUCLEIC ACIDS AND OTHER MOLECULES | SLC2A9, SLC2A2, TRMT1 | CA2 1073/4885SLC34A1 68/4885FDPS 2866/4885 |
| US-20260049123-A1 | BISPECIFIC ANTIBODIES PROMOTE NATURAL KILLER CELL-MEDIATED ELIMINATION OF HIV-1 RESERVOIR CELLS | FCGR3B, CD4, HAVCR2 | CA2 4426/4885SLC34A1 2893/4885FDPS 3963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.